Comatose patients resuscitated from out-of-hospital cardiac arrest (OHCA) exhibit a systemic inflammatory response, as indicated by elevated interleukin-6 (IL-6) levels, which is associated with increased mortality. Tocilizumab, an IL-6 receptor antagonist that reduced C-reactive protein response and markers of myocardial injury in a phase II OHCA trial.

中文翻译：

---

白细胞介素 6 阻断改变院外心脏骤停时的血浆代谢组


从院外心脏骤停 （OHCA） 中复苏的昏迷患者表现出全身炎症反应，如白细胞介素 6 （IL-6） 水平升高所示，这与死亡率增加有关。托珠单抗，一种 IL-6 受体拮抗剂，在 II 期 OHCA 试验中降低了 C 反应蛋白反应和心肌损伤标志物。